New MRI-Guided radiation aims to hit tumors harder, spare healthy tissue

NCT ID NCT05903430

Recruiting now Disease control Sponsor: The Christie NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether doctors can deliver very high doses of radiation to tumors in the abdomen or chest using an MRI-guided machine, while limiting harm to nearby organs. About 60 people with abdominal or lung cancer will take part. The main goal is to see if the treatment can be completed successfully in most patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-guided stereotactic ablative radiotherapy (SABR) using a high-field MR-Linac
What this could lead to: If successful, this approach could enable more precise, high-dose radiation treatment for abdominal and lung cancers while reducing damage to nearby healthy organs.
What could go wrong: This is an early feasibility study with only 60 participants, so results may not apply broadly. The main goal is to see if the technique is practical, not yet to prove it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABDOMINAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABDOMINAL CANCER LUNG CANCER

Contacts and locations

Locations

The Christie NHS Foundation Trust
RECRUITING

Manchester, United Kingdom, M204BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.